osimertinib,tepotinib
astrazeneca,merck
['insight-2', 'lcsm,(-blcsm)', 'osimertinib', 'tepotinib']
insight-2: osimertinib + tepotinib for met amplified egfrmut, after 1l osimertinib metamp occurs in 36% orr 54% tepotinib alone = low response 18% needed dose reduction #esmo22 #lcsm 
Thoracic medical oncologist | Consultant @ChelwestFT | Vice Chair @BTOGorg | Skier, when snow permits.